Semaglutide (Ozempic / Wegovy / Rybelsus / 胰妥讚)

Semaglutide

共 4 個適應症評級

🔬 實證評級速查

🔵 A 中度證據Semaglutide (Ozempic / Wegovy / Rybelsus / 胰妥讚) × 第二型糖尿病

白話說：證據中等，有一定的支持。

證據分數 76 分（滿分 100）　·　發布狀態：可正常參考

🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

US FDA 態度：支持
展開原文引用
「The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app…」
EU EFSA 態度：支持
展開原文引用
「Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a…」
UK NHS 態度：支持
展開原文引用
「Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th…」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。產製日期 2026-06-09 ·　版本 v4。本評級僅供衛教參考，不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面

🔬 實證評級速查

🔵 A 中度證據Semaglutide (Ozempic / Wegovy / Rybelsus / 胰妥讚) × 心血管疾病 (CVD)

白話說：證據中等，有一定的支持。

證據分數 72 分（滿分 100）　·　發布狀態：可參考，但附帶但書

⚠️ 機構立場可能有偏向🔬 存在反面證據🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

US FDA 態度：支持
展開原文引用
「The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app…」
EU EFSA 態度：支持
展開原文引用
「Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a…」
UK NHS 態度：支持
展開原文引用
「Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th…」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。產製日期 2026-06-09 ·　版本 v5。本評級僅供衛教參考，不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面

🔬 實證評級速查

🔵 A 中度證據Semaglutide (Ozempic / Wegovy / Rybelsus / 胰妥讚) × 脂肪肝 MASLD/MASH

白話說：證據中等，有一定的支持。

證據分數 72 分（滿分 100）　·　發布狀態：可參考，但附帶但書

⚠️ 部分研究有廠商利益🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

US FDA 態度：支持
展開原文引用
「The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app…」
EU EFSA 態度：支持
展開原文引用
「Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a…」
UK NHS 態度：支持
展開原文引用
「Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th…」

🔬 實證評級速查

🔵 A 中度證據Semaglutide (Ozempic / Wegovy / Rybelsus / 胰妥讚) × 肥胖 (BMI ≥30)

白話說：證據中等，有一定的支持。

證據分數 68 分（滿分 100）　·　發布狀態：可參考，但附帶但書

⚠️ 部分研究有廠商利益🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

US FDA 態度：支持
展開原文引用
「The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app…」
EU EFSA 態度：支持
展開原文引用
「Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a…」
UK NHS 態度：支持
展開原文引用
「Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th…」